• 1
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1278, iii.
  • 2
    Vane JR, Botting RM. A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 418.
  • 3
    WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. URL:
  • 4
    Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
  • 5
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 13028.
  • 6
    Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
  • 7
    Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 20219.
  • 8
    US Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). URL:
  • 9
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796806.
  • 10
    Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008; 59: 13717.
  • 11
    Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 13240.
  • 12
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195207.
  • 13
    Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care–based inception cohort. Arthritis Rheum 2005; 52: 22939.
  • 14
    Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 3350.
  • 15
    Cush JJ, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1928.
  • 16
    Cush JJ, Jasin HE, Johnson R, Lipsky PE. Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum 1990; 33: 62333.
  • 17
    Menkes CJ. Effects of disease-modifying anti-rheumatic drugs, steroids and non-steroidal anti-inflammatory drugs on acute-phase proteins in rheumatoid arthritis. Br J Rheumatol 1993; 32 Suppl 3: 148.
  • 18
    Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24: 91104.
  • 19
    Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 91620.
  • 20
    Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. Oxford: Cochrane Collaboration; 2011. URL:
  • 21
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W6594.
  • 22
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 23
    Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002; 31: 1409.
  • 24
    Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 2006; 59: 34253.
  • 25
    Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336: 6015.
  • 26
    Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 32159.
  • 27
    Ellegaard K, Christensen R, Torp-Pedersen S, Terslev L, Holm CC, Konig MJ, et al. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford) 2011; 50: 50612.
  • 28
    Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 170613.
  • 29
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 153958.
  • 30
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 55760.
  • 31
    Thomson Reuters/Truven Health Analytics. Micromedex 1.0. 2011. URL:
  • 32
    Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 155973.
  • 33
    Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790804.
  • 34
    Cohick CB, Furst DE, Quagliata S, Corcoran KA, Steere KJ, Yager JG, et al. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein. J Lab Clin Med 1994; 123: 7217.
  • 35
    Haslock I. The effect of alclofenac on clinical and laboratory measures of disease activity in rheumatoid arthritis: preliminary results. Curr Med Res Opin 1975; 3: 298308.
  • 36
    Bachmann F, Stroescu O, Hartl W. Double blind and dosage studies on tolectine in rheumatoid arthritis. Z Allgemeinmed 1975; 51: 13826. In German.
  • 37
    Tsvetkova ES. Comparative effectiveness of Voltaren and indomethacin in rheumatoid arthritis (according to the data of a double-blind study). Ter Arkh 1978; 50: 2630. In Russian.
  • 38
    Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591602.
  • 39
    Loose LD, Sipe JD, Kirby DS, Kraska AR, Weiner ES, Shanahan WR, et al. Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug. Br J Rheumatol 1993; 32 Suppl 3: 1925.
  • 40
    Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissila M, Sahlberg D, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 28290.
  • 41
    Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 19218.
  • 42
    Furst DE, Kolba KS, Fleischmann R, Silverfield J, Greenwald M, Roth S, et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29: 43646.
  • 43
    Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al, and the Etoricoxib Rheumatoid Arthritis Study Group. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002; 3: 10.
  • 44
    Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002; 29: 162330.
  • 45
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 107185.
  • 46
    Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, Chowienczyk P. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36: 2659.
  • 47
    Mizushima Y, Ichikawa Y, Kashiwazaki S, Sugawara S, Nagaya I, Hirohata K, et al. Clinical evaluation of TS-110 against rheumatoid arthritis: dose finding study using placebo. Rinsho Iyaku 1997; 13: 891921. In Japanese.
  • 48
    Geusens PP, Truitt K, Sfikakis P, Zhao PL, DeTora L, Shingo S, et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand J Rheumatol 2002; 31: 2308.
  • 49
    Williams GW, Kivitz AJ, Brown MT, Verburg KM. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. Clin Ther 2006; 28: 20421.
  • 50
    GD Searle. Valdecoxib NDA 21-341. Statistical review(s), part IV: Tables 46 and 53, results for secondary endpoints (protocols 060 and 061). 2002; p. 60, 64–5. URL:
  • 51
    Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis G, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 2004; 58: 103341.
  • 52
    Medicines and Healthcare Products Regulatory Agency. UK public assessment report for Prexige 100mg tablets (Lumiracoxib) PL 00101/0677. 2007. URL:
  • 53
    Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al, the Phase II Rofecoxib Rheumatoid Arthritis Study Group. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999; 21: 1688702.
  • 54
    GlaxoSmithKline. COX-2 inhibitor study in patients with rheumatoid arthritis. identifier: NCT00113308. A phase III, 12-week, multicentre, double-blind, randomised, placebo- and active comparator-controlled, parallel group study to investigate the efficacy and safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in adults with rheumatoid arthritis. URL:
  • 55
    Pavelka K, Nayiager S, Kivitz A, Patel N, Yu S, Sloan V. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13-week, randomized, double-blind study [abstract]. Ann Rheum Dis 2004; 63 Suppl I: 280.
  • 56
    Schnitzer TJ, Gitton X, Jayawardene S, Sloan VS. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. Curr Med Res Opin 2005; 21: 15161.
  • 57
    Truitt K, Lee M, DeTora LM, Anderson M, Zhao PL. Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 12.5 and 25 mg in adult patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl: S369.
  • 58
    Curtis SP, Maldonado-Cocco J, Losada BR, Gallagher AE, Ng J, Mukhopadhyay S, et al. Treatment with etoricoxib (MK-0663), a COX-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis [abstract]. European League Against Rheumatism: Abstracts from the 2001 Annual Congress, Prague, Czech Republic, June 13–16, 2001.
  • 59
    Novartis. A 13 week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of two doses of lumiracoxib (200 and 400 mg qd) in patients with rheumatoid arthritis using celecoxib (200 mg bid) as a comparator. CCOX189A0114. 2009. URL:
  • 60
    GD Searle. Celecoxib NDA 20-998. Medical review, part 12: Table A.41, C-reactive protein (protocol 023). 2005; p. 208. URL:
  • 61
    Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002; 41: 100816.
  • 62
    Abe T, Saito T, Hashimoto H, Nagaya I, Ozaki S, Inoue H, et al. [ Title only in Japanese.] Progress in Medicine 2006; 26 Suppl 3: 2788819.
  • 63
    Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008; 118: 16180.
  • 64
    Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 128191.
  • 65
    Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 8405.
  • 66
    Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 11823.
  • 67
    Masferrer JL, Needleman P. Anti-inflammatories for cardiovascular disease. Proc Natl Acad Sci U S A 2000; 97: 124001.
  • 68
    Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48: 7882.
  • 69
    Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 2007; 16: 76272.
  • 70
    Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169: 1419.
  • 71
    Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 2008; 371: 2703.
  • 72
    Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 136774.
  • 73
    Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010; 340: c365.
  • 74
    Cannon CP, Chen C, Curtis SP, Viscusi J, Ahmed T, Dibattiste PM. A comparison of cardiovascular biomarkers in patients treated for three months with etoricoxib, celecoxib, ibuprofen, and placebo. Arch Drug Inf 2008; 1: 413.